Assessing Perrigo (PRGO) Valuation After Impairment-Driven Loss And Weaker Full-Year Sales Outlook

Simply Wall St.05-20

Perrigo (PRGO) stock is in focus after the company reported a sharply higher first quarter net loss, driven by a US$330.8 million goodwill impairment charge, and reaffirmed guidance for full year net ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2637829020?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","is_english":true,"pubTime":"2026-05-20 22:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2637829020","market":"sg","top_or_hot":-1,"title":"Assessing Perrigo (PRGO) Valuation After Impairment-Driven Loss And Weaker Full-Year Sales Outlook","media":"Simply Wall St.","content":"<div>\n<p>Perrigo (PRGO) stock is in focus after the company reported a sharply higher first quarter net loss, driven by a US$330.8 million goodwill impairment charge, and reaffirmed guidance for full year net ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-prgo/perrigo/news/assessing-perrigo-prgo-valuation-after-impairment-driven-los\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Perrigo (PRGO) Valuation After Impairment-Driven Loss And Weaker Full-Year Sales Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Perrigo (PRGO) Valuation After Impairment-Driven Loss And Weaker Full-Year Sales Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-20 22:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-prgo/perrigo/news/assessing-perrigo-prgo-valuation-after-impairment-driven-los><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Perrigo (PRGO) stock is in focus after the company reported a sharply higher first quarter net loss, driven by a US$330.8 million goodwill impairment charge, and reaffirmed guidance for full year net ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-prgo/perrigo/news/assessing-perrigo-prgo-valuation-after-impairment-driven-los\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PRGO","symbol_name":"百利高","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-prgo/perrigo/news/assessing-perrigo-prgo-valuation-after-impairment-driven-los","article_id":"2637829020","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-prgo/perrigo/news/assessing-perrigo-prgo-valuation-after-impairment-driven-los","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2637829020","pubTimestamp":1779287104,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Perrigo (PRGO) stock is in focus after the company reported a sharply higher first quarter net loss, driven by a US$330.8 million goodwill impairment charge, and reaffirmed guidance for full year net sales to decline.\nSee our latest analysis for Perrigo.\nThe earnings miss, goodwill impairment and reaffirmed outlook for lower net sales have coincided with clear selling pressure, with the share price down 10.1% over the past month and the 1 year total shareholder return declining 58.6%,...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"PRGO":"百利高"},"translate_title":"在减值驱动的损失和全年销售前景疲软后评估Perrigo(PRGO)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRGO":1.5},"content_text":"Perrigo (PRGO) stock is in focus after the company reported a sharply higher first quarter net loss, driven by a US$330.8 million goodwill impairment charge, and reaffirmed guidance for full year net sales to decline. See our latest analysis for Perrigo. The earnings miss, goodwill impairment and reaffirmed outlook for lower net sales have coincided with clear selling pressure, with the share price down 10.1% over the past month and the 1 year total shareholder return declining 58.6%, pointing to fading momentum. If this kind of reset in sentiment has you looking around the market for other ideas, it may be worth scanning 29 healthcare AI stocks to find different health focused opportunities tied to AI trends. With Perrigo trading at US$10.61, carrying an intrinsic discount flag and sitting well below analyst price targets, the key question is whether recent losses are already fully reflected in the stock or if the market is overlooking any potential for recovery. AdvertisementMost Popular Narrative: 35.7% Undervalued With Perrigo closing at $10.61 against a narrative fair value of $16.50, the spread between price and story is wide enough to examine closely.  Recent new business wins in US store-brand OTC have outpaced distribution losses for the first time since the 2024 reset, with net new contract gains expected to add $75M+ to sales in the second half, directly supporting a step-change in revenue growth and operating income.  Read the complete narrative. Want to see how flat top line assumptions can still support a higher valuation? The narrative leans heavily on margin repair and a richer future profit multiple. Curious which specific earnings and return hurdles underpin that $16.50 figure and the discount rate behind it? The full story connects those pieces in a tight valuation case. Result: Fair Value of $16.50 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, there are clear pressure points, including softer infant nutrition trends and ongoing cost inflation. These factors could cap margin repair and limit how much earnings power improves. Find out about the key risks to this Perrigo narrative. Next Steps With sentiment pulled sharply in both directions by risks and rewards, this is a moment to move quickly and test the data yourself. Start with 4 key rewards and 1 important warning sign. Looking for more investment ideas? If Perrigo has sharpened your thinking, do not stop here. Broaden your watchlist with focused stock ideas filtered by quality, value and resilience.  Target potential mispricing by scanning companies flagged as quality opportunities in the 54 high quality undervalued stocks. Strengthen your defensive core by reviewing companies highlighted in the 66 resilient stocks with low risk scores. Get ahead of the crowd by checking companies surfaced by the screener containing 21 high quality undiscovered gems.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2637829020","isCrawlerRequest":true}